ABCL vs LLY

AbCellera continues to present a compelling, albeit high-risk, investment thesis due to its differentiated AI-powered antibody discovery platform and vast addressable market. The competitive moat, built on proprietary technology and partnerships, remains robust. Leadership is focused, and a solid cash position provides runway. However, the path to diversified, high-margin royalty revenue is long a...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...